US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis

US Cystic Fibrosis Foundation and European Cystic Fibrosis Society

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Non-tuberculous mycobacteria (NTM) are ubiquitous environmental organisms that can cause chronic pulmonary infection, particularly in individuals with pre-existing inflammatory lung disease such as cystic fibrosis (CF). Pulmonary disease caused by NTM has emerged as a major threat to the health of individuals with CF but remains difficult to diagnose and problematic to treat. In response to this challenge, the US Cystic Fibrosis Foundation (CFF) and the European Cystic Fibrosis Society (ECFS) convened an expert panel of specialists to develop consensus recommendations for the screening, investigation, diagnosis and management of NTM pulmonary disease in individuals with CF. Nineteen experts were invited to participate in the recommendation development process. Population, Intervention, Comparison, Outcome (PICO) methodology and systematic literature reviews were employed to inform draft recommendations. An anonymous voting process was used by the committee to reach consensus. All committee members were asked to rate each statement on a scale of: 0, completely disagree, to 9, completely agree; with 80% or more of scores between 7 and 9 being considered 'good' agreement. Additionally, the committee solicited feedback from the CF communities in the USA and Europe and considered the feedback in the development of the final recommendation statements. Three rounds of voting were conducted to achieve 80% consensus for each recommendation statement. Through this process, we have generated a series of pragmatic, evidence-based recommendations for the screening, investigation, diagnosis and treatment of NTM infection in individuals with CF as an initial step in optimising management for this challenging condition.

Original languageEnglish (US)
Pages (from-to)i1-i22
JournalThorax
Volume71
DOIs
StatePublished - Jan 1 2016
Externally publishedYes

Fingerprint

Mycobacterium
Cystic Fibrosis
Lung Diseases
Politics
Committee Membership
Mycobacterium Infections
Lung
Health
Infection
Population

Keywords

  • Bacterial Infection
  • Cystic Fibrosis

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis. / US Cystic Fibrosis Foundation and European Cystic Fibrosis Society.

In: Thorax, Vol. 71, 01.01.2016, p. i1-i22.

Research output: Contribution to journalArticle

@article{5c452bab2b594eafa40b4e6597696e91,
title = "US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis",
abstract = "Non-tuberculous mycobacteria (NTM) are ubiquitous environmental organisms that can cause chronic pulmonary infection, particularly in individuals with pre-existing inflammatory lung disease such as cystic fibrosis (CF). Pulmonary disease caused by NTM has emerged as a major threat to the health of individuals with CF but remains difficult to diagnose and problematic to treat. In response to this challenge, the US Cystic Fibrosis Foundation (CFF) and the European Cystic Fibrosis Society (ECFS) convened an expert panel of specialists to develop consensus recommendations for the screening, investigation, diagnosis and management of NTM pulmonary disease in individuals with CF. Nineteen experts were invited to participate in the recommendation development process. Population, Intervention, Comparison, Outcome (PICO) methodology and systematic literature reviews were employed to inform draft recommendations. An anonymous voting process was used by the committee to reach consensus. All committee members were asked to rate each statement on a scale of: 0, completely disagree, to 9, completely agree; with 80{\%} or more of scores between 7 and 9 being considered 'good' agreement. Additionally, the committee solicited feedback from the CF communities in the USA and Europe and considered the feedback in the development of the final recommendation statements. Three rounds of voting were conducted to achieve 80{\%} consensus for each recommendation statement. Through this process, we have generated a series of pragmatic, evidence-based recommendations for the screening, investigation, diagnosis and treatment of NTM infection in individuals with CF as an initial step in optimising management for this challenging condition.",
keywords = "Bacterial Infection, Cystic Fibrosis",
author = "{US Cystic Fibrosis Foundation and European Cystic Fibrosis Society} and Floto, {R. Andres} and Olivier, {Kenneth N.} and Lisa Saiman and Daley, {Charles L.} and Herrmann, {Jean Louis} and Nick, {Jerry A.} and Noone, {Peadar G.} and Diana Bilton and Paul Corris and Gibson, {Ronald L.} and Hempstead, {Sarah E.} and Karsten Koetz and Sabadosa, {Kathryn A.} and Isabelle Sermet-Gaudelus and Smyth, {Alan R.} and {van Ingen}, Jakko and Wallace, {Richard J.} and Kevin Winthrop and Marshall, {Bruce C.} and Haworth, {Charles S.}",
year = "2016",
month = "1",
day = "1",
doi = "10.1136/thoraxjnl-2015-207360",
language = "English (US)",
volume = "71",
pages = "i1--i22",
journal = "Thorax",
issn = "0040-6376",
publisher = "BMJ Publishing Group",

}

TY - JOUR

T1 - US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis

AU - US Cystic Fibrosis Foundation and European Cystic Fibrosis Society

AU - Floto, R. Andres

AU - Olivier, Kenneth N.

AU - Saiman, Lisa

AU - Daley, Charles L.

AU - Herrmann, Jean Louis

AU - Nick, Jerry A.

AU - Noone, Peadar G.

AU - Bilton, Diana

AU - Corris, Paul

AU - Gibson, Ronald L.

AU - Hempstead, Sarah E.

AU - Koetz, Karsten

AU - Sabadosa, Kathryn A.

AU - Sermet-Gaudelus, Isabelle

AU - Smyth, Alan R.

AU - van Ingen, Jakko

AU - Wallace, Richard J.

AU - Winthrop, Kevin

AU - Marshall, Bruce C.

AU - Haworth, Charles S.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Non-tuberculous mycobacteria (NTM) are ubiquitous environmental organisms that can cause chronic pulmonary infection, particularly in individuals with pre-existing inflammatory lung disease such as cystic fibrosis (CF). Pulmonary disease caused by NTM has emerged as a major threat to the health of individuals with CF but remains difficult to diagnose and problematic to treat. In response to this challenge, the US Cystic Fibrosis Foundation (CFF) and the European Cystic Fibrosis Society (ECFS) convened an expert panel of specialists to develop consensus recommendations for the screening, investigation, diagnosis and management of NTM pulmonary disease in individuals with CF. Nineteen experts were invited to participate in the recommendation development process. Population, Intervention, Comparison, Outcome (PICO) methodology and systematic literature reviews were employed to inform draft recommendations. An anonymous voting process was used by the committee to reach consensus. All committee members were asked to rate each statement on a scale of: 0, completely disagree, to 9, completely agree; with 80% or more of scores between 7 and 9 being considered 'good' agreement. Additionally, the committee solicited feedback from the CF communities in the USA and Europe and considered the feedback in the development of the final recommendation statements. Three rounds of voting were conducted to achieve 80% consensus for each recommendation statement. Through this process, we have generated a series of pragmatic, evidence-based recommendations for the screening, investigation, diagnosis and treatment of NTM infection in individuals with CF as an initial step in optimising management for this challenging condition.

AB - Non-tuberculous mycobacteria (NTM) are ubiquitous environmental organisms that can cause chronic pulmonary infection, particularly in individuals with pre-existing inflammatory lung disease such as cystic fibrosis (CF). Pulmonary disease caused by NTM has emerged as a major threat to the health of individuals with CF but remains difficult to diagnose and problematic to treat. In response to this challenge, the US Cystic Fibrosis Foundation (CFF) and the European Cystic Fibrosis Society (ECFS) convened an expert panel of specialists to develop consensus recommendations for the screening, investigation, diagnosis and management of NTM pulmonary disease in individuals with CF. Nineteen experts were invited to participate in the recommendation development process. Population, Intervention, Comparison, Outcome (PICO) methodology and systematic literature reviews were employed to inform draft recommendations. An anonymous voting process was used by the committee to reach consensus. All committee members were asked to rate each statement on a scale of: 0, completely disagree, to 9, completely agree; with 80% or more of scores between 7 and 9 being considered 'good' agreement. Additionally, the committee solicited feedback from the CF communities in the USA and Europe and considered the feedback in the development of the final recommendation statements. Three rounds of voting were conducted to achieve 80% consensus for each recommendation statement. Through this process, we have generated a series of pragmatic, evidence-based recommendations for the screening, investigation, diagnosis and treatment of NTM infection in individuals with CF as an initial step in optimising management for this challenging condition.

KW - Bacterial Infection

KW - Cystic Fibrosis

UR - http://www.scopus.com/inward/record.url?scp=85017039626&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017039626&partnerID=8YFLogxK

U2 - 10.1136/thoraxjnl-2015-207360

DO - 10.1136/thoraxjnl-2015-207360

M3 - Article

C2 - 26666259

AN - SCOPUS:85017039626

VL - 71

SP - i1-i22

JO - Thorax

JF - Thorax

SN - 0040-6376

ER -